|
Dec 11 |
PDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Co...
Study evaluating PDS0101-KEYTRUDA®... |
|
Dec 11 |
PDS Biotechnology Announces Resignation of James Loughlin from Board of Directors...
PRINCETON, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- PDS... |
|
Dec 03 |
PDS Biotechnology to Present at the 12th Annual LD Micro Main Event...
PRINCETON, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- PDS... |
|
Nov 25 |
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019...
PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS... |
|
Nov 22 |
PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® - GM-CSF Combination to Overcome Tumor I...
BERKELEY HEIGHTS, N.J., June 19, 2019 (GLOBE... |
|
Nov 07 |
PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update...
PRINCETON, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- PDS... |
|
Nov 06 |
PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting...
Dr. Lauren V. Wood, M.D. to present data from... |
|
Oct 22 |
PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101...
Clinical batches support upcoming Phase 2 PDS101... |
|
Oct 03 |
PDS Biotechnology Corp. Announces Clinical Collaboration with Merck...
PDS0101- KEYTRUDA® (pembrolizumab) Combination... |
|
Oct 01 |
PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Da...
Data demonstrated regression of lesions in 60%... |
|
Sep 19 |
PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial...
60% of evaluable patients demonstrated a clinical... |
|
Sep 03 |
PDS Biotechnology to Present at the 21st Annual H.C. Wainwright Global Investment Conference...
BERKELEY HEIGHTS, N.J., Sept. 03, 2019 (GLOBE... |
|
Aug 01 |
PDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update...
BERKELEY HEIGHTS, N.J., Aug. 01, 2019 (GLOBE... |
|
Jul 03 |
PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...
BERKELEY HEIGHTS, N.J., July 03, 2019 (GLOBE... |
|
Jul 03 |
PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...
BERKELEY HEIGHTS, N.J., July 03, 2019 (GLOBE... |
|
May 28 |
PDS Biotechnology to Present at the 9th Annual LD Micro Invitational...
BERKELEY HEIGHTS, N.J., May 28, 2019 (GLOBE... |
|
May 28 |
PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase...
BERKELEY HEIGHTS, N.J., May 29, 2019 (GLOBE... |
|
May 15 |
PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in...
BERKELEY HEIGHTS, N.J., May 15, 2019 (GLOBE... |
|
May 14 |
PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update...
BERKELEY HEIGHTS, N.J., May 14, 2019 (GLOBE... |
|
Apr 08 |
PDS Biotechnology Appoints Stephen Glover to its Board of Directors...
BERKELEY HEIGHTS, N.J., April 08, 2019 (GLOBE... |
|
Mar 18 |
PDS Biotechnology Completes Merger with Edge Therapeutics...
Shares of Combined Company to Commence Trading... |
|
Feb 21 |
Edge Therapeutics Announces Full Year 2018 Financial Results...
BERKELEY HEIGHTS, N.J., Feb. 21, 2019 (GLOBE... |
